This Article Full Text Full Text (PDF) CME: Take the course for this article: Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Syste... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Dahabreh, I. J. Articles by Murray, S. PubMed PubMed Citation Articles by Dahabreh, I. J. Articles by Murray, S.

Breast Cancer

Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

^aNational University of Athens, Medical School, Athens, Greece; ^bDepartment of Medical Oncology, Athens Medical Center, Athens, Greece; ^c1^st Department of Oncology, Metropolitan Hospital, Athens, Greece; ^dDepartment of Mathematics, National University of Athens, Athens, Greece; ^eDepartment of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; ^fDepartment of Molecular Biology and Genetics, Metropolitan Hospital, Athens, Greece

Key Words. Trastuzumab • Adjuvant chemotherapy • Breast cancer • HER-2 • Systematic review • Meta-analysis

Correspondence: Correspondence: Samuel Murray, Ph.D., Department of Molecular Biology and Genetics, Metropolitan Hospital, 1, Ethnarhou Makariou & Venizelou Street, Piraeus, Greece. Telephone: +30-210-4809254/213; Fax: +30-210-4809257; e-mail: smurray{at}metropolitan-hospital.gr

Received January 2, 2008; accepted for publication April 2, 2008.

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Background. We performed a systematic review and meta-analysis to compare treatment outcomes for human epidermal growth factor receptor (HER)-2–positive breast cancer patients receiving adjuvant chemotherapy with or without trastuzumab.

Methods. We identified randomized clinical trials comparing adjuvant chemotherapy with or without trastuzumab in patients with resectable breast cancer. Fixed-effects meta-analysis was used to combine data.

Results. Five eligible trials were identified, reporting outcomes on 13,493 women. Fixed-effects analysis showed disease-free survival to be superior for trastuzumab-treated patients (risk ratio [RR], 0.62; 95% confidence interval [CI], 0.56–0.68). Superiority was also observed for patients receiving trastuzumab with respect to mortality (RR, 0.66; 95% CI, 0.57–0.77), locoregional recurrence (RR, 0.58; 95% CI, 0.43–0.77), and distant recurrence (RR, 0.60; 95% CI, 0.52–0.68). Patients receiving trastuzumab with chemotherapy had a higher risk for congestive heart failure (RR, 7.60; 95% CI, 4.07–14.18) and left ventricular ejection fraction decline (RR, 2.09; 95% CI, 1.84–2.37). A higher risk for central nervous system metastasis as the first recurrence event (RR, 1.60; 95% CI, 1.06–2.40) was also noted in patients receiving trastuzumab.

Conclusions. The use of trastuzumab should be considered an integral part of the adjuvant therapy of HER-2–positive breast cancer patients.